Targeted drug delivery with liposome technology reduces IOP, maintains results
VANCOUVER, British Columbia — Subconjunctival injection of a liposome-latanoprost agent using nanotechnology reduced IOP in patients with glaucoma, and results were sustained through 3 months, a speaker said here.
“Having sustained delivery is a ‘no-brainer.’ There’s more efficient drug use. There’s less drug wastage. The drug is independent of the patient’s compliance … You have targeted delivery of the drug to the right place, and you have round-the-clock delivery so you’re not worried about any loss of effect,” Tina T. Wong, FRCOphth, FRCSEd, PhD, said at the World Glaucoma Congress.
Tina T. Wong
In the open-label, single-arm, phase 1 study, 100 µL of the combination agent, LipoLat, was injected in the superior bulbar conjunctiva of six patients with either ocular hypertension or very mild primary open-angle glaucoma. All of the patients were on monotherapy and had an IOP between 22 mm Hg and 36 mm Hg after wash-out. IOP was measured after the injection at 1 hour, 7 days, 14 days, and at 1, 2 and 3 months, Wong said.
IOP reduction of up to about 10 mm Hg was sustained at 3 months, Wong said. No patient had discomfort due to subconjunctival injection; redness, pain and burning; or anterior chamber activity. Two patients experienced dry eyes, and lubricants were prescribed.
“We showed that LipoLat is well-tolerated without any substantial safety issues,” Wong said. Wong continues to follow-up patients and said that the pressure-lowering effects have continued to 5 months.
A multicenter, phase 2 trial is planned.
Disclosure: Wong is co-inventor and named patent holder for the product presented in the presentation, with sponsorship by Allergan.